Daiichi Sankyo announced better-than-expected Q1FY25 result, with all key parameters exceeding expectation. Q1 revenue increased 24% to ¥436B, mainly driven by 59% growth in Enhertu sales to ¥130B.
What is covered in the Full Insight:
Introduction
Overwhelming Q1 Result
Enhertu Momentum Continues
FY25 Guidance Reaffirmed; Revision Expected
Visibility Beyond Enhertu- New Drug Approval Potential
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.